327 results about "Abnormal cell" patented technology

Disclosed compounds of general formula (1)

wherein

• L, Q₁, Q₂, X, Y, R^a, R^b, R^c, R¹, R², R³ and R⁴ are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.

An apparatus and method for medical practitioners to detect the presence of abnormal cells including cancerous and pre-cancerous cells by using a transport capsule containing an imaging apparatus including UV sources and fluorescence detectors for obtaining images and fluorescence data of biological cells and tissue. The method includes the steps of scanning biological tissue using an ultra-violet (UV) source to obtain fluorescence data, transferring fluorescence data and/or images using a radio frequency (RF) or other suitable means to a personal computer (PC) system, analyzing the image and/or fluorescence data in the PC, identifying -tissues with precancerous and cancerous cells, and optionally determining their precise location, and assessing the accuracy of the calculated fluoroscopic images.

The high-voltage battery unit 400, for each of the plurality of areas A1 to AN grouped by the temperature distribution pattern set in step S110, the reference internal resistance Rrc(n) indicating an internal resistance of the battery cell 450 based on the correlation to the temperature is acquired based on the area representative temperature Ta(n) detected by any one of the temperature sensors 44k in the individual area An (step S140); the detected internal resistance Rdm(m) based on the detected voltage V(x) and the detected current value I is acquired for each battery module 40x; the presence or absence of an abnormal cell in an individual battery module 40x is determined based on the reference internal resistance Rrm(n) of the battery module 40x based on the reference internal resistance Rrc(n) and the detected internal resistance Rdm(m) (steps S180 to S210).

The present invention provides compositions and methods for treating abnormal cell proliferation and for regulating angiogenesis. In particular, multivalent protein conjugates (MVPs) are constructed to include multiple ligand-binding domains of different receptors and utilized to target multiple, different ligands that are involved in regulation of cell growth and neovascularization. The MVPs of the present invention can be used to treat various conditions associated with abnormal cell proliferation and angiogenesis such as cancer and cardiovascular disorders, as well as to promote wound healing.

The present invention achieves rapid identification of pathogens, bacteria, cancer cells and other abnormal human and animal cells. In one embodiment, the system of the present invention comprises a first subsystem that obtains and processes images of specimens of pathogens, bacteria, and other abnormal cells, and a second subsystem that accepts the images, isolates the particular features of the image using advanced image segmentation, and then rapidly and accurately identifies the pathogens, bacteria and other abnormal cells by using a pattern recognition process wherein the segmented or isolated features of the original image are compared to known reference images.

Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient.

Since the novel 2,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.

The invention described herein provides for methods of profiling cellular models of disease. Cellular systems biology is the investigation of the integrated and interacting networks of genes, proteins, and metabolites that are responsible for normal and abnormal cell functions. Methods and reagents for the profiling a disease state, the treatment of a disease state and assaying of treatments of a disease state are provided.

Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Methods for identifying Rheb effectors are provided. The Rheb effectors can be Rheb agonists or antagonists and can be utilized as lead compounds for the development of drugs for the treatment of diabetes or diseases associated with abnormal cell growth. Non-human, transgenic animals over-expressing Rheb protein, and methods of making such transgenic animals, are also provided.

The invention relates to five-membered heterocycle pyrimidine compounds, their pharmaceutical acceptable salt or pharmaceutical acceptable solvate and a preparation method thereof. The five-membered heterocycle pyrimidine compounds possess a c-Met inhibitory activity and have a structure as shown in the general formula 1. The invention also relates to a drug combination which contains the compounds and applications of the compounds in preparation of drugs used for prevention and treatment of in vivo Hepatocyte Growth Factor Receptor (HGFR) related abnormal cell proliferation, morphologic change and hyperkinesis associated diseases, angiogenesis or cancer metastasis associated diseases, and especially for prevention and treatment of tumor growth and metastasis.

The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. The compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

The invention relates to a hemolytic agent for blood leukocyte five-classification counting and an application thereof. The hemolytic agent comprises a hemolytic agent A and a hemolytic agent B. The hemolytic agent A comprises a polyoxyethylene nonionic surfactant, an organic acid, a quaternary ammonium salt cationic surfactant cosolvent, a stabilizing agent and an osmotic regulator; the hemolytic agent B comprises alkaline inorganic salt and an osmotic regulator. When compared with the result detected by a standard hemolytic agent produced by BeckmanCoulter company, the hemolytic agent of the invention has good correlation and high accuracy. Especially, when abnormal cells exist in a blood specimen, the hemolytic agent has high warning sensitivity and good specificity, and exhibits the most beneficial effect.

This invention relates to an illuminated vaginal speculum suitable for cervical speculoscopy to enable a user to distinguish abnormal cells from normal cells, the illuminated vaginal speculum comprising: a first blade having a first open part and a first holding part; a second blade, which is pivoted to the first blade, comprising a second open part and a second holding part; an adjuster installed between the first and the second blades for adjusting the relative angle between the first and the second open parts; and a first illumination member connected to the first open part or the second open part, the first illumination member being capable of emitting light of a color different from that of the normal cells so as to enable the user to distinguish abnormal cells from normal cells.

Methods, computer readable storage media and systems which can be used for analyzing labeled biological samples, identifying chromosomal aberrations, identifying genetically abnormal cells and/or computationally scanning the samples using randomly or randomized scanning methods are provided. Specifically, the present invention can be used to analyze FISH-stained samples and automatically identify chromosomal aberrations associated with abnormal intensity ratio of stained occurrences in the sample.

The invention discloses a segmentation method of pathological section unconventional cells based on a multi-scale hybrid segmentation model. The method comprises steps that positive and negative samples are respectively scaled to low-resolution, medium-resolution and high-resolution images, the full convolutional network algorithm is utilized for training to acquire a convergent low-resolution segmentation model, a medium-resolution segmentation model and a high-resolution model; a multi-scale hybrid segmentation model is acquired through fusion by a model integration method; after the effective discriminating area of a new pathological section is processed through utilizing the data enhancement method during testing, the processed effective discriminating area is inputted to the multi-scale hybrid segmentation model, the probability of each pixel in the effective segmentation area is outputted, pixels with probability values greater than the threshold t are taken as abnormal cell pixels and are recorded as 1, remaining pixels are taken as normal cell pixels and are recorded as 0, binary images predicted by the multi-scale hybrid segmentation model are acquired, and post-processingon the binary images is carried out to acquire the final segmentation result. The method is advantaged in that high precision is realized, and a Dice value is above 0.869.

The invention provides, in certain embodiments, compounds, pharmaceutical compositions and methods for modulating the functions of estrogen receptor alpha 36, for preventing and/or treating diseases related to estrogen receptor alpha 36, for preventing and/or treating respiratory diseases such as asthma, for inducing cell death and/or inhibiting cell proliferation and for preventing and/or treating diseases involving abnormal cell proliferation such as cancers.

A system for facilitating microscope-based specimen analysis is disclosed. The system includes an improved optical microscope, which may be used, in one application, to analyze cell and tissue samples from specimens obtained from patients, to facilitate inspection of suspicious materials and identification of atypical or abnormal cells and further expert review. The system includes a motorized plate, an automatic focusing sub-system, an improved light source, an improved simple plug connector for direct hookup of the microscope to an external computer, and an electronic image capturing and analyzing sub-system for automatic scanning of the sample and for electronic capture and storage of images indicative of the specimen.

The invention discloses a differential blood count reagent which comprises the following components: (1) a cyanine anion compound selected form compounds expressed by the formula I or formula II, (2) an anode surfactant expressed by the formula III, IV or V and (3) at least one nonionic surfactant. The invention also discloses a kit containing the differential blood count reagent and a method of the differential blood count. By utilizing the reagent, the kit and the method, five subclasses of leucocytes can be quickly identified within a very short time, four-classification count is at least carried out, and immaturate cells and abnormal cells can be distinguished.

The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

An apparatus for image elastic scattering spectroscopy is disclosed that is comprised of a light source for generating polarized light. Means are provided to convey the polarized light to a target. A collector receives light reflected from the target. A detector is responsive to the collector for generating images at both parallel and perpendicular polarizations for each of a plurality of wavelengths. A range finder detects a distance to the target. Control electronics control the image generation and the range finder. The apparatus may be configured to image areas on the surface of the body or configured so as to be inserted into various body cavities. Typically, the apparatus will be used in conjunction with an analyzer for analyzing the images for evidence of abnormal cells. Methods of gathering data and of screening for abnormal cells are also disclosed.

The invention discloses a cervical cell pathological slice automatic judging method with high and low resolution combination, which is characterized in that the method comprises the following steps: extracting a single cell mass region on a low-resolution cervical pathological slice image; extracting a single cell mass region from the low-resolution cervical pathological slice image; identifying suspicious abnormal cell clusters from low-resolution cell clusters; mapping suspected abnormal cell mass regions into high resolution slice images; semantically segmenting pathological cells from thehigh-resolution region of suspicious cell clusters and interpreting the type; according to the type, quantity and confidence of the segmented lesion cells, establishing the feature set of the slice, and then classifying the lesion type of the whole slice. The invention takes cell cluster as processing and recognition unit, utilizes classification neural network model to quickly identify suspiciousabnormal cell cluster on low-resolution digital slice, then divides out pathological cell on high-resolution suspicious area and judges its type, at the same time, improves recognition accuracy and recognition efficiency.

The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and/or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds, tranilast compounds, retinoic acid compounds, resveratol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.

Disclosed are new dihydropteridinones of general formula (I)

wherein the groups R¹ to R⁵, R^a to R^c, W, Q₁ and Q₂ have the meanings given in the claims and specification, the isomers thereof and the use thereof for preparing a pharmaceutical composition for the treatment of diseases characterised by excessive or abnormal cell proliferation.